Fundamental analysis · SEC EDGAR · TTM through 29/03/2026

Fundamental analysis of Johnson & Johnson

JNJ · NYSE · Pharmaceutical Preparations

Fundamental quality

ATTRACTIVE

78

out of 100

Breakdown by area

I.GrowthEPS: 8% · Revenue: 5.9%
51
II.ProfitabilityNet margin: 21.8% · ROE: 25.9%
91
III.Financial healthNet debt/EBITDA: 0.6x · FCF: 18.5%
93

Source: SEC EDGAR · TTM through 29/03/2026

Reading the numbers

On average over recent years, earnings per share grew 8% a year and revenue advanced 5.9% a year.

On profitability, Johnson & Johnson shows a net margin of 21.8%, a gross margin of 67.8%, an ROE of 25.9%.

Its financial health shows net debt of 0.6 times its EBITDA and a free cash flow margin of 18.5%.

Adding up growth, profitability and financial strength, the traffic light gives JNJ a fundamental quality of 78 out of 100. To also know whether it's cheap or expensive, the price is missing: enter it in the tool and you'll get the valuation verdict (P/E against its sector).

The thresholds are general and the system doesn't judge qualitative factors. See the full methodology and use this analysis as a first filter, never as a final decision.

Is Johnson & Johnson cheap or expensive?

That depends on the current price. Look it up, enter it in the tool and get the full valuation verdict (P/E against its sector).

Compute the valuation →
Advertising

Where to buy Johnson & Johnson?

Brokers you can use to invest in U.S. and European stocks.

Compare the brokers →